Evaluation of myocardial perfusion and viability in patients with stable coronary artery disease have now become the basic source of information in qualification for revascularization or optimal medical therapy. This article describes all the available methods of non-invasive imaging of myocardial perfusion and viability.
Introduction
The 2010 European Society of Cardiology guidelines concer ning the indications for revascularisation [1] define, based on the results of clinical studies and multicentre metaanalyses, the role Evaluation of myocardial perfusion and viability in coronary artery disease in view of the new revascularization guidelines Based on these guidelines, myocardial perfusion assessment complete with the diagnosis of the extent and location of perfusion disorders provides the basis for the selection of patients with stable coronary artery disease or intermediate probability of coronary artery disease and normal resting contractility of the left ventricle for further invasive diagnostic (coronary angiography) and treat ment (revascularisation) procedures [2] .
And also, based on the same guidelines, myocardial viability assessment focused on the region supplied by the narrowed/oc cluded coronary artery forms the basis for the selection of pa tients with impaired contractility of the left ventricle for revascu larisation [3, 4] .
It is important that both these cases are relevant to stable patients or patients with intermediate probability of coronary artery disease for whom the postponement of therapeutic procedure by attempting preliminary noninvasive diagnostic methods should not cause any irreversible myocardial changes (necrosis) or any other major adverse cardiac events (MACE) [2] . Patients diagnosed using noninvasive methods for perfusion and viability assessment are those for whom it is possible -under no time pressure -'cito' -to consider the benefits and drawbacks of the selected dia gnostic and treatment procedures, and to prepare an appropriate management plan based on the clinical data and test results of a given patient. As has been stressed by the authors of the current guidelines concerning the indications for revascularisation, many patients should rather be considered eligible for planned coronary artery bypass grafting (CABG) than for emergency percutane ous transluminal coronary angioplasty (PTCA).
Individualisation of therapeutic procedures has now become the order of the day as a result of many years of experience and efficacy assessment of revascularisation versus optimal pharma cological therapy. 
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Myocardial perfusion
Stable coronary artery disease causes insufficient blood supply to the myocardium during physical exertion (or under stress) and thus restricts patient's physical performance -the impairment of the coronary flow reserve is indicated under stress by such symptoms as coronary pain or its equivalent. The lack of these symptoms referred to as "silent ischemia" poses a danger for patients -it does not restrict their activity, does not trigger any danger signal and therefore can cause irreversible myocardial changes (necrosis). Patients with stable coronary artery disease can have normal resting myocardial contractility, which does not exclude stressinduced impairment of myocardial contractile function during physical exertion or immediately thereafter (hi bernating and/or stunned myocardium). In the COURAGE study, in a subset of 300 patients with significant coronary stenosis who underwent revascularisation, the reduced risk of a major adverse cardiac event (MACE) was only reported for those patients who were observed to have an area of more than 10% of left ventricle affected with stressinduced blood supply disorders before the procedure -only those patients benefited from invasive treatment compared to optimal medical therapy [5] .
Therefore a wellplanned revascularisation procedure should aim at eliminating ischemia, and not only the coronary artery stenosis [6] . 
Myocardial viability
The diagnosis of potentially irreversible myocardial dysfunction is important on account of the higher risk of death in patients with coronary artery disease and reduced myocardial contractility [7] .
Only 57% of the patients suffering from coronary artery disease with left ventricular ejection fraction below 35% can survive 4 years com pared to the 92% survival rate among patients with ejection frac tion over 50% [3, 8] . Postrevascularisation myocardial damage is potentially reversible in about 25-40% of the patients with coro nary artery disease and LV dysfunction [9] . The metaanalysis of 3088 patients with coronary artery disease demonstrated that the death rate was 4 times lower among postsurgical patients with dysfunctional, but viable myocardium compared to patients on pharmacological treatment [3] . No significant difference was de termined between the efficacy of pharmacological and surgical treatments among patients with no features of viable myocardium [3] . At the same time, one should be aware that the risk of death in the perioperative period and within a year from the coronary artery bypass graft (CABG) surgery in patients with permanent myocardial damage is twice as high compared to postsurgical patients with dysfunctional myocardium and retained myocardial viability (10% and 7.7% vs 4% and 3.2% respectively). About 35% of CABG or PTCA patients do not benefit from the treatment due to the fact that revascularisation comprises the region of transmural myocardial necrosis [3] . 
SPECT-BASED VIABILITY ASSESSMENT
Scintigraphic assessment of myocardial viability requires only resting SPECT image, and preferably resting ECGgated SPECT (GSPECT) image.
It is the cheapest and most widely available viability imaging method among 99mTcMIBIbased functional SPECT proce dures -only a viable myocardium shows an appropriate level of perfusion at rest and systolic increase in the myocardial thick ness during GSPECT registration [16, 17] . During GSPECT acquisi tion a viable myocardium shows at least 50% of the maximal marker accumulation compared to the reference best bloodsupplied myocardial region (assuming that it is nondamaged myocardium) and systolic increase in the myocardial thickness of at least 10% in ECGgated SPECT registration. These SPECT parameters show that the myocardial functions are likely to improve in more than 70% of postrevascularisation patients [17] . In other studies, the level of marker accumulation during SPECT registration below 30% of the maximal reference value shows that there is an 80% probability of myocardial nonviability, i.e. transmural or nearly transmural necrosis [14] . However, as shown in multicentre metaanalyses, SPECTbased viability values are overestimated and their specific ity is only 49% with sensitivity at 88% [18] .
PET-based myocardial perfusion and viability assessment PET-BASED PERFUSION ASSESSMENT
PET is considered a "gold standard" in myocardial perfusion assessment -the sensitivity and specificity of this method in the assessment of perfusion disorders in patients with coronary artery disease have been determined in 8 independent studies at 93-97% respectively -on average 93% and 88-100% -on average 92% [19] , and furthermore it enables quantitative assessment of perfu sion in mL/g of myocardial tissue/min using N13NH 3 
PET-BASED VIABILITY ASSESSMENT
Fluorodeoxyglucose PET (FDGPET) has recently been considered a "gold standard" in myocardial viability assessment [21] , although currently this role has been taken over by MRI. In or increased FDG accumulation indicates a strong probability of hibernated myocardium [24] .
However, PET is a costly procedure and has lower spatial resolution than MRI with strong enhancement after gadolinium administration. The comparison of PET and MRI results showed 95% compatibility [25] .
CMR-based myocardial perfusion and viability assessment CMR-BASED PERFUSION ASSESSMENT
The first pass of paramagnetic contrast agent through myo cardium, i.e. socalled 'firstpass CMR' is performed twice: under pharmacological stress (dipyridamole, adenosine) and at rest [26] . 
CMR-BASED VIABILITY ASSESSMENT
Over the past few years a number of publications [29] [30] [31] included reports on CMRbased myocardial necrosis imaging after the administration of paramagnetic contrast agent and with the signal ratio for viable and nonviable myocardium of up to 500%. This method known as 'delayed enhancement' (DE) or 'late gadolinium enhancement' (LGE) has been successfully used for determining the presence, location and extent of both acute and chronic myocardial necrosis. The location, shape and transmural extent of delayed enhancement in the myocardium during DE MR examination is morphologically identical to the extent of necro sis determined in tetrazoliumbased histopathological examination [32] . Increased GdDTPA accumulation overlaps with the histologi cal cell changes in the necrotic region, typical of an infarct, and is about 130% higher than in a viable myocardium [33] . DE MR examination gives a possibility of determining the presence and extent of necrosis with spatial resolution greater than PET (gold standard thus far) or SPECT, and can be used to forecast improve ment of myocardial functions after revascularisation (Figure 3 ).
Based on the results thus far, it was determined that the lack of delayed enhancement or the transmural extent of necrosis of up to 50% of the myocardial thickness increases the probability of postrevascularisation improvement of leftventricular efficiency (Figure 4) [34] .
Summary
Despite the existing discrepancies in the results of the useful ness studies concerning myocardial perfusion and viability as sessments when qualifying patients with coronary artery disease for revascularisation, it is the prevailing view among cardiolo gists that any such information is relevant and new, less invasive imaging methods increase the comfort of making therapeutic decisions which are correct and beneficial for patients.
Review
Currently, the assessment of usefulness of noninvasive met hods for perfusion and viability analyses based on the author's own experiences and available publications is given in the attached tables (Table 1, Myocardial perfusion assessment based on noninvasive imaging methods -additionally included echocardiography with dobutamine aimed at analysing functional disorders, i.e. indirectly the effects of perfusion disorders; --nonavailable method/no diagnostic value/nonobjective assessment; + -low availability/low diagnostic value/low cost/ /reduced objectivity; ++ -moderate availability/moderate diagnostic value/moderate cost/good objectivity; +++ -good availability/reliable and objective diagnostic value/ /moderate cost; ++++ -widely available method/high objectivity/high cost;? -developing/growing in popularity Myocardial perfusion assessment based noninvasive imaging methods -additionally included echocardiography with dobutamine aimed at analysing the potential post revascularisation functional improvement;--nonavailable method/no diagnostic value/nonobjective assessment; + -low availability/low diagnostic value/low cost/reduced objectivity; ++ -moderate availability/moderate diagnostic value/moderate cost/moderate objectivity; +++ -good availability/reliable and objective diagnostic value/low cost; ++++ -widely available method/high objectivity/high cost;? -developing/growing in popularity
